Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
about
Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesAn update on the management of urinary tract infections in the era of antimicrobial resistance.Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coliExtended-spectrum β-lactamase-producing Enterobacteriaceae in cell phones of health care workers from Peruvian pediatric and neonatal intensive care units.Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective.Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.An update on emerging therapies for urinary tract infections.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Biliary diseases as main causes of pyogenic liver abscess caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia.Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.High rates of antimicrobial resistance of ESBL-producing Enterobacteriaceae isolated from clinical samples in Northeast of Brazil.In vitro interaction between cefepime and amoxicillin-clavulanate against extended-spectrum β-lactamase-producing Escherichia coli.Piperacillin-tazobactam as alternative to carbapenems for ICU patients.Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious Diseases Society of America/American Thoracic Society guidelines.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems.Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase Klebsiella pneumoniae among cancer patients.Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?
P2860
Q28249617-DE907786-1295-43C7-B087-A1FB10F89023Q30244815-38AC1378-BA6F-44C1-8440-0D9655F4EABDQ33598276-FAAF4FDA-1DDD-4A3D-AB9E-AD4D868D1D2AQ33776486-AD77BF4F-4A2F-4294-8D51-2023186BCF5BQ37597908-DCE87192-BBC1-42B0-8E3D-FA67E81B81B5Q38088261-B57CD6EA-18EA-4753-A5BD-B81B275D80B6Q38115356-D2CEB42F-83C1-4997-920E-A4B7898BE374Q38165138-D2784FE0-EAC4-4BED-9A17-24B7A8A9D0CFQ38185120-24B86E08-FDB5-4C1F-BEDF-14A640A9DDDAQ38232197-A3CA604E-AE2F-4001-AAE9-C5DA07CCB0DDQ38384662-AC397DC0-7586-4538-AA25-535897461D89Q38497797-E7028C6A-2DBA-4F47-9759-5B04752CDF5FQ38511551-A7556318-A266-41AD-845B-6BE8B9ACC525Q38620812-D101E8C0-42FF-4295-803C-220CB8A85627Q38681779-42116471-077A-40FF-BD44-5EA502E6727FQ38739545-B22F823B-EDE8-4A5D-91D8-E0409163678BQ38741453-07959A22-0BF1-41DE-B23E-900F71E26657Q38751454-95D9F1E7-A622-4C26-BAB5-0ED4B5A4E780Q38792841-2A521414-F988-42E6-8519-F278F73891B1Q38864569-3E28E975-F384-4452-8253-597F4A8E912FQ38981397-BAA7E979-7E1E-40C1-A99B-B72F5555B1EFQ40479700-5B3CCFF6-ECD3-48FF-A5EE-F29622E7E497Q40612416-B07AE7CC-7124-4EF6-8F06-68F494E6A1FEQ40812219-E48EA0DC-B36C-4A3E-B9F8-AF53C0B1F752Q41217004-E437C6F5-27A1-4CFF-AE38-FD5D2E972633Q41779878-A1613BAB-BBBC-4748-82AF-E1A4EDB51FD8Q41994579-ED1F3B7A-C942-452F-8745-ED45FC4BF628Q43188135-F418309F-6DB8-45D2-85D2-D11C848D59C8Q45711115-BE6B9E79-AC9E-466A-A5CA-0D1ED4BFD41DQ47312597-36EF64CE-BE93-47D2-ACE2-E462567A577AQ47427370-80F94D80-8A06-4C1C-AE19-5A8401945B51Q47566277-8E4E4F36-E529-49BF-9D14-FD6EFD4DB110Q52695014-2E417618-CBA4-4EA1-99AA-013262B5C0CAQ53693902-7B632091-4629-4F84-A15E-11B02DDF2F51Q53811523-639B06B3-28AC-45E2-90BA-35ED1542393BQ54508230-D9A06A85-FD20-49CB-80A7-E993F271FD26Q58694612-286E924A-1ABF-4329-8A15-A350A0386F2E
P2860
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@ast
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@en
type
label
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@ast
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@en
prefLabel
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@ast
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@en
P2093
P2860
P356
P1476
Impact of cefepime therapy on ...... eumoniae and Escherichia coli.
@en
P2093
Adnan Yousuf
Ashish Bhargava
Dania Hatahet
Dror Marchaim
George Alangaden
Hiro Rahbar
Jason M Pogue
Jennifer Veltman
Jing J Zhao
Joseph Ellsworth
P2860
P304
P356
10.1128/AAC.05419-11
P407
P577
2012-04-30T00:00:00Z